Search

Your search keyword '"Brunetto M."' showing total 862 results

Search Constraints

Start Over You searched for: Author "Brunetto M." Remove constraint Author: "Brunetto M."
862 results on '"Brunetto M."'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

2. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

3. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

4. Hierarchical black hole triples in young star clusters: impact of Kozai-Lidov resonance on mergers

6. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

7. Artificial Intelligence and liver: Opportunities and barriers

8. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

9. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

10. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

12. HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

13. Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts

14. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

15. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

16. The application of artificial intelligence in hepatology: A systematic review

17. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

18. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study

19. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

20. Prediction of response to obeticholic acid in primary biliary cholangitis: Development and validation of the OCA response score (ORS)

23. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

24. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

25. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

26. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

27. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

28. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

29. On introducing automatic test case generation in practice: A success story and lessons learned

30. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

31. EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

34. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

39. Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301.

40. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

41. Clinical features of patients with new onset of autoimmune hepatitis following SARS-CoV-2 vaccination

42. Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

43. Safety of direct-acting antivirals for Hepatitis C infection and direct oral anticoagulants co-administration: an Italian multicentric study

44. Cholestasis impacts on performance of non invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

45. Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis

46. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

Catalog

Books, media, physical & digital resources